Navigation Links
BioMarin Announces Third Quarter 2008 Financial Results
Date:10/28/2008

" target="_new">http://www.BMRN.com.

Date: October 28, 2008

Time: 5:00 p.m. ET (22:00 CET)

U.S. / Canada Dial-in Number: 800.299.9630

International Dial-in Number: 617.786.2904

Participant Code: 70952576

Replay Dial-in Number: 888.286.8010

Replay International Dial-in Number: 617.801.6888

Replay Code: 67493262

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme, Kuvan, and Aldurazyme; the financial performance of the BioMarin as a
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioMarin Corrects Information Included in Bloomberg Article
2. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Citi Biotech Day
5. BioMarin Announces Roll-Out of National PKU Registry
6. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
7. BioMarin to Present at the Collins Stewart Growth Conference
8. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
9. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
10. BioMarin to Host Research and Development Day June 5th
11. BioMarin to Present at the Bank of America Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 ... report is available in its catalogue: ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... are materials that are readily decomposed by ... from conventional non-degradable packaging in terms of ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Chelating Agents ... About Chelating Agent A chelating agent ... bonds with metal ions, thereby forming a metal-ion ... metal-ions have on chemical processes, formulations, and the ...
(Date:8/27/2014)... August 27, 2014 “We are honored ... vendors,” said Ven Thangaraj, CEO of Radiant Sage. “We ... are taking the imaging corelab market to a different ... and research organizations to efficiently and effectively manage the ... data to be analyzed and read by trained physicians. ...
(Date:8/27/2014)... Research and Markets has announced ... & Paper Industry Report 2014" report to their ... & Paper Industry Report 2014 is a professional and ... enzyme for pulp & paper industry. The ... definitions, classifications, applications and industry chain structure. The enzyme ...
Breaking Biology Technology:Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Global Enzyme for Pulp & Paper Industry Report 2014 2
... Wis. - TomoTherapy, Inc. , the medical device ... has rapidly grown sales of its precision radiation therapy technology ... researchers, is riding high. , ,So high that it can ... recently completed an $8.2 million expansion project to quadruple its ...
... Calling the destruction of human embryos a line that society should ... would have overturned his ban on new federal funding for human ... House of Representatives. , ,"It crosses a moral boundary that our ... in announcing the veto, the first of his presidency. , ,The ...
... a week since its first notification, TDS Telecom ... are still being approached by a fraudulent company offering significant ... known as "Vishing," which is similar to online "Phishing" schemes. ... a 35 percent discount on their long-distance service and are ...
Cached Biology Technology:Cash-rich TomoTherapy has no plans for IPO 2Cash-rich TomoTherapy has no plans for IPO 3Cash-rich TomoTherapy has no plans for IPO 4Bush vetoes stem cell research bill 2Bush vetoes stem cell research bill 3TDS warns of continuing "Vishing" attempts 2
(Date:8/27/2014)... (June, 2014) Outstanding basic research, a growing ... dedication to patient care have earned the Herbert ... Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 ... National Cancer Institute (NCI). The grant renews the ... Comprehensive Cancer Centers in New York City and ...
(Date:8/27/2014)... A growing number of studies have shown ... the pathogenesis of Parkinson,s disease. Previous studies ... Medical University in China have shown that ... injury, reduced divalent metal transporter 1 expression, ... substantia nigra of rotenone-induced Parkinson,s disease rats. ...
(Date:8/27/2014)... Camp Complex of fires had consumed 24,939 acres of ... 35,530 as of eight hours ago. , Lightning ... District of the Klamath National Forest when a thunderstorm ... but three of those fires are now 100 percent ... and their size at containment: Delta, 150 acres; Sutcliffe, ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... Roque Vinicio Cspedes, a junior at the University ... with a minor in Spanish, has been awarded a ... mentorship. SOARS is a paid summer research internship for ... This summer Cspedes will travel to Boulder, Colo. ...
... Phrases such as survival of the fittest and every ... of political and social competition in American culture; however, ... conflict across almost all known organisms. So what makes ... sometimes seem to be preferred over cooperation? Psychologists ...
... of the UN Conference on Climate Change (COP15) to be ... IARU to organise this conference as part of the run-up ... to try and capture some of the enormous research energy ... climate change. Thus, the focus of the conference is on ...
Cached Biology News:Meteorology student SOARS toward excellence, overcomes obstacles 2United we stand: When cooperation butts heads with competition 2
Request Info...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Recombinant Equine IL-4, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: